Gaps persist despite doubling of new products for neglected diseases

A rigorous assessment of drug and vaccine development for neglected diseases that shows some improvement over the last decade but still major gaps has been published in the Lancet today. Only 4% of the new therapeutic products registered between 2000-11 were for 11% of the global disease burden, and only 4 new chemical entities that can lead to truly new products were approved. 

Read more...